Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Patient-derived organoids support individualized treatment for ovarian cancer patients
EF 2023-24
Résumé
Background: Ovarian cancer (OC) is a significant global health concern, ranking as the fifth leading cause of cancer-related deaths among women. Notably, specific populations in Quebec, such as French Canadians and Jewish communities, exhibit a higher prevalence of hereditary OC mutations. While platinum-based chemotherapy is initially effective, tumors often develop resistance, necessitating alternative treatments like PARP inhibitors (PARPi), which offers fewer side effects than standard chemotherapy. However, the variable response to PARPi among patients underscores the need for improved predictive tests.
Objective: To determine whether three-dimensional tissue cultures from individual OC patients can be used to predict PARPi response in the frontline setting.
Methods: Three-dimensional OC model, derived from OC patients at two time points (time of biopsy and after treatment with either platinum-based drugs or PARPi) will be established. The appearance of cells and special markers specific for OC will be performed with Dr. Basile Tessier-Cloutier, a Gynecologic Pathologist, for both the parent tumor and the cell model. Genetic analysis at McGill Genome Centre, clinical data from Gynecologic Oncologist Dr. Annie Leung, and statistical analyses will be integrated to identify features associated with treatment response or resistance.
Preliminary Data: results show successful generation of representative three-dimensional tissue cultures, morphologically and molecularly similar to the parent tumor.
Impact: This proposal aims to predict treatment response and enhance understanding of genetic mechanisms influencing drug response. Ultimately, this research seeks to advance personalized OC treatment, informing more effective clinical decisions for improved patient outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506091
Name
Hana Kattreen
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Patient-derived organoids support individualized treatment for ovarian cancer patients
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dna Repair Pathway; Genomic Profiling; High-Grade Serous Ovarian Cancer (Hgsc); Immunohistochemical Expression; Parp Inhibitors (Parpis); Patient-Derived Organoids (Pdos); Personalized Therapeutics; Platinum-Based Therapy; Treatment Response; Whole Genome Sequencing
Abstract
Background: Ovarian cancer (OC) is a significant global health concern, ranking as the fifth leading cause of cancer-related deaths among women. Notably, specific populations in Quebec, such as French Canadians and Jewish communities, exhibit a higher prevalence of hereditary OC mutations. While platinum-based chemotherapy is initially effective, tumors often develop resistance, necessitating alternative treatments like PARP inhibitors (PARPi), which offers fewer side effects than standard chemotherapy. However, the variable response to PARPi among patients underscores the need for improved predictive tests.
Objective: To determine whether three-dimensional tissue cultures from individual OC patients can be used to predict PARPi response in the frontline setting.
Methods: Three-dimensional OC model, derived from OC patients at two time points (time of biopsy and after treatment with either platinum-based drugs or PARPi) will be established. The appearance of cells and special markers specific for OC will be performed with Dr. Basile Tessier-Cloutier, a Gynecologic Pathologist, for both the parent tumor and the cell model. Genetic analysis at McGill Genome Centre, clinical data from Gynecologic Oncologist Dr. Annie Leung, and statistical analyses will be integrated to identify features associated with treatment response or resistance.
Preliminary Data: results show successful generation of representative three-dimensional tissue cultures, morphologically and molecularly similar to the parent tumor.
Impact: This proposal aims to predict treatment response and enhance understanding of genetic mechanisms influencing drug response. Ultimately, this research seeks to advance personalized OC treatment, informing more effective clinical decisions for improved patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hana, Kattreen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~